Loading stock data…
SOPH
$4.79-0.36 (-6.99%)
Market ClosedLast close May 11
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SOPHiA GENETICS SA in the Healthcare sector is trading at $4.79. The stock is currently 16% below its 52-week high of $5.70, remaining 7.9% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why SOPH maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.79
Potential Upside
5%
Whystock Fair Value$5.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic mod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$361.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-155.68%
Volume
Today's trading volume
270,190
Recent News
SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary
Moby summary of SOPHiA GENETICS S.A.'s Q1 2026 earnings call
SOPHiA GENETICS Q1 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Revenue growth and re
SOPHiA Genetics (SOPH) Q1 2026 Earnings Transcript
In the first quarter, we delivered revenue growth of 22% year-over-year. In addition to processing more data volume than ever, we also achieved adjusted gross margin of 75.4%, demonstrating the unique scalability of our hyper-efficient analytics platform.
BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8
SOPHiA GENETICS SA (NASDAQ:SOPH) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 15, 2026, BTIG raised its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The firm said management “signaled confidence across the business” following investor meetings with President […]
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.